
Work Here?
Work Here?
Work Here?
Asahi Kasei produces a wide range of products including performance polymers, medical devices, and residential construction materials. The company operates by applying polymer science and engineering to create specific components, such as battery separators for electric vehicles and dialysis equipment for patient care. Unlike many specialized competitors, Asahi Kasei maintains a highly diversified portfolio that spans from basic chemicals to advanced healthcare, allowing it to balance industrial stability with growth in emerging technology sectors. Its goal is to drive global expansion and sustainability by developing materials and services that support carbon neutrality, clean energy, and community health.
Industries
Industrial & Manufacturing
Energy
Healthcare
Company Size
10,001+
Company Stage
IPO
Headquarters
Tokyo, Japan
Founded
1922
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Asahi Kasei has signed its first Chinese licensing deal for Acetolyte™, a novel acetonitrile-containing electrolyte for lithium-ion batteries. HighChem Shanghai will produce and sell the electrolyte to battery manufacturers in China under a non-exclusive agreement. The partnership targets China's expanding market for high-performance batteries driven by electric vehicle and energy storage system growth. HighChem Shanghai will leverage its established customer base in the Chinese battery industry to drive market adoption. Acetolyte™ offers high ionic conductivity, enabling better battery performance at low temperatures and improved durability at high temperatures. The technology allows for smaller, more energy-dense battery packs whilst reducing manufacturing costs. Asahi Kasei previously expanded Acetolyte™ through licensing partnerships in Europe.
Asahi Kasei has installed its forward osmosis–membrane distillation (FO–MD) system at Japanese pharmaceutical CDMO Peptistar's active pharmaceutical ingredient (API) manufacturing facility. The system dehydrates and concentrates liquids without heat or pressure, reducing freeze-drying time and accelerating API production. The technology addresses manufacturing challenges for heat-sensitive next-generation APIs like peptides and oligonucleotides. Traditional concentration methods risk quality degradation through heating or precipitation. Asahi Kasei's system uses osmotic pressure and vapour pressure differences across membranes to prepare high-concentration solutions whilst maintaining ingredient composition and avoiding precipitation. Peptistar is operating the system at manufacturing scale for batches up to 100 litres, evaluating it for GMP-compliant production. Asahi Kasei is studying prospects for future commercialisation as part of its Life Science growth strategy.
German battery manufacturer EAS Batteries has begun sales of its ultra-high-power lithium-ion LFP cell, incorporating Asahi Kasei's acetonitrile-containing electrolyte Acetolyte. The UHP601300 LFP 22 cell delivers 2,550 W/kg under continuous discharge, a 60% improvement over conventional electrolytes. With 22 Ah nominal capacity, the cell achieves 3,760 W/kg under two-second pulse discharge and offers 2,400 cycles at 5C/5C discharge rate. Asahi Kasei signed a licensing agreement with EAS Batteries in November 2025, with serial production starting in March 2026. The companies are collaborating on a 46xxx cell format targeted for 2026 launch, primarily designed for low-voltage electric vehicle batteries. They plan to sublicense their combined technologies to global manufacturers for mobility applications.
Asahi Kasei is delaying the start-up of its Canadian battery separator plant to 2029 or later, following Honda Motor's postponement of its Ontario electric vehicle plans. The Japanese materials supplier originally planned to begin operations in mid-2027. The facility was designed to produce 700 million square metres of battery separators annually, enough for approximately one million EVs. Honda holds a 25% stake in the project but pushed back its own Ontario EV plant from 2028 to 2030 last May. Asahi Kasei has slashed its North American EV market forecast for 2030 to two million vehicles from eight million, citing weakened customer demand. The company will supply North America by exporting separators from Japan and is exploring demand from AI data centre markets to accelerate the plant's opening.
Asahi Kasei is expanding its battery separator production in the US with a new Hipore coating facility in North Carolina, targeting growing electric vehicle and energy storage demand. The facility, set to start production in mid-2027, will focus on advanced separator technologies aligned with regional safety standards. The move positions Asahi Kasei closer to North American battery and EV manufacturers, targeting higher-value coated separator products. Shares in TSE:3407 are trading at ¥1,634.5, with a year-to-date return of 15.1% and 78.1% over the past year. The expansion faces execution risks including potential delays and cost overruns, alongside competitive pressure from rivals like Toray, Sumitomo Chemical and SK IE Technology. Financial impact is expected to be phased, allowing time for customer qualification and contract negotiations.
Find jobs on Simplify and start your career today
Industries
Industrial & Manufacturing
Energy
Healthcare
Company Size
10,001+
Company Stage
IPO
Headquarters
Tokyo, Japan
Founded
1922
Find jobs on Simplify and start your career today